StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MIRMBullishAnalyst Target Updateanalyst
Medium materiality6/10

Mirum Pharmaceuticals (MIRM) PT Raised to $189 at Raymond James

Nov 4, 2026, 8:21 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Bullish analyst view, tempered by the shares’ move since the signal and the uncertainty inherent in price targets.

AI summary

What happened, with direct paths to the underlying reporting

Raymond James raised its price target to $189, versus the posted price of $87.03. The target implies substantial upside, though it is an analyst opinion and the shares have already risen 11.42% since the signal.

  • Target: $189; posted price: $87.03.
  • Price change since signal: +11.42%.

Key facts

  1. 01

    Target: $189

  2. 02

    Posted price: $87.03

  3. 03

    Analyst firm: Raymond James

  4. 04

    Analyst: Steven Seedhouse

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.